Shashita Inamdar
Psychiatry · San Diego, CANPI 1003861139
Payments from drug & device makers
Across 615 payments — averaging $23.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$2K
- AbbVie$1K
- Brainsway USA Inc$1K
- Otsuka America Pharmaceutical, Inc.$1K
- Lundbeck LLC$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- plus $6K from 23 others
What the payments were for
- Travel & lodging$1,1668%
- Food & beverage$13,26592%
- Education$470%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 79 | $1,967 |
| AbbVie(2 entities) | 85 | $1,356 |
| Brainsway USA Inc | 3 | $1,303 |
| Otsuka America Pharmaceutical, Inc. | 67 | $1,266 |
| Lundbeck LLC | 58 | $1,180 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 34 | $1,012 |
| Tris Pharma Inc | 45 | $732 |
| Vanda Pharmaceuticals Inc. | 32 | $674 |
| Neurocrine Biosciences, Inc. | 23 | $630 |
| Axsome Therapeutics, Inc. | 25 | $551 |
| Supernus Pharmaceuticals, Inc. | 28 | $536 |
| Takeda Pharmaceuticals U.S.A., Inc. | 31 | $515 |
| Sunovion Pharmaceuticals Inc. | 17 | $370 |
| Indivior Inc. | 13 | $285 |
| Alkermes, Inc. | 12 | $267 |
| Corium, LLC | 10 | $257 |
| Neos Therapeutics, LP | 11 | $256 |
| Teva Pharmaceuticals USA, Inc. | 5 | $190 |
| Tempus AI, Inc | 4 | $179 |
| E.r. Squibb & Sons, L.L.C. | 5 | $162 |
| Ironshore Pharmaceuticals Inc. | 6 | $149 |
| CSL Behring | 1 | $125 |
| Shire North American Group Inc | 6 | $118 |
| Sage Therapeutics, LLC | 1 | $106 |
| Alfasigma USA, Inc. | 5 | $97 |
| Merck | 3 | $67 |
| Lilly USA, LLC | 2 | $45 |
| Livanova USA, Inc. | 2 | $45 |
| Collegium Pharmaceutical, Inc. | 2 | $42 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- deep tms$1,166
- SPRAVATO$369
- INGREZZA$147
- Hizentra$125
- Austedo XR$121
- CAPLYTA$115
- COBENFY$111
- ZULRESSO$106
- Brainsway Deep TMS$106
How this compares
$14,478 in reported general payments places this provider in the 90th percentile of 4,954 psychiatry providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 28 | $1,448 |
| Escitalopram Oxalate | 19 | $343 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 21 | $338 |
| Trazodone Hcl | 14 | $264 |
| Temazepam | 11 | $183 |
| Alprazolam | 11 | $173 |
| Quetiapine Fumarate | 23 | $165 |
| Bupropion Hcl SrBupropion Hcl | 13 | $120 |
| Clonazepam | 24 | $97 |
| Gabapentin | 11 | $56 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in San Diego
- Eric ChavezSan Diego$15.5M
- Charmaine SemeniukSan Diego$8.9M
- Jonathan MeyerSan Diego$2.3M
- Vishaal MehraSan Diego$1M
- Elly LeeIrvine$49.8M
- Daniel ChuehOrange$17.9M
- Lara ShirikjianTorrance$12.6M
- John DuffySanta Ana$12M
- Marina BusselPlaya Vista$12M
- Sherry SoefjeOceanside$11.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.